Geranium Maculatum Root

For the treatment of Adult Growth Hormone Deficiency, the dosage of Geranium Maculatum Root must be highly individualized. Clinical guidelines generally recommend a 'start low, go slow' approach to minimize side effects.

• Initial Dose: 0.15 mg to 0.30 mg per day, administered via subcutaneous injection.
• Maintenance Dose: The dose may be increased by increments of 0.1 mg to 0.2 mg every 4 to 8 weeks based on the patient's clinical response and serum IGF-1 (Insulin-like Growth Factor 1) levels.
• Maximum Dose: Typically does not exceed 1.0 mg per day in adults. Older patients may require significantly lower doses to avoid adverse effects like fluid retention.

For Allergenic Immunotherapy, the dosage follows a build-up phase followed by a maintenance phase. The initial concentration is often as low as 0.01 BAU (Bioequivalent Allergen Units), increasing weekly until a maintenance dose of 100-500 BAU is reached.

In pediatric patients, dosing is primarily calculated based on body weight or body surface area (BSA).

• Pediatric Growth Failure: The standard dose is 0.18 mg/kg to 0.35 mg/kg of body weight per week. This total weekly dose is usually divided into daily subcutaneous injections.
• Turner Syndrome: Doses up to 0.375 mg/kg per week are often utilized to maximize height velocity.
• Idiopathic Short Stature: Dosing is typically 0.30 mg/kg to 0.47 mg/kg per week.

> Note: Pediatric use must be closely monitored by a pediatric endocrinologist to ensure the epiphyseal plates (growth plates) remain open. Treatment must cease once the growth plates have fused.

Renal Impairment

Geranium Maculatum Root clearance is reduced in patients with significant renal dysfunction. While specific dose-adjustment tables are not always provided, clinicians should monitor for increased sensitivity to the drug and adjust the dose downward if signs of fluid retention or hypertension occur. In patients on dialysis, the drug should be administered after the dialysis session.

Hepatic Impairment

Patients with hepatic impairment may have reduced IGF-1 production in response to the drug. Consequently, higher doses might be required to achieve the desired clinical effect, but this must be balanced against the risk of decreased metabolic clearance of the drug itself.

Elderly Patients

Patients over the age of 65 are more prone to the side effects of growth hormone therapy. It is recommended to start at the lowest possible dose (e.g., 0.1 mg/day) and titrate very cautiously.

• Injection Technique: For growth hormone indications, the drug is injected subcutaneously (under the skin). Common sites include the upper arms, thighs, or abdomen. It is critical to rotate injection sites daily to prevent lipoatrophy (localized loss of fat tissue).
• Timing: Injections should ideally be administered in the evening to mimic the body's natural nocturnal surge of growth hormone.
• Storage: Most liquid formulations must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. If the solution becomes cloudy or contains particles, it should be discarded.
• Preparation: If using a lyophilized powder, gently swirl the vial during reconstitution. Do not shake, as this can denature the delicate protein structures and render the medication ineffective.

If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the normal schedule. Do not double the dose to make up for a missed one. If more than three consecutive doses are missed, contact your healthcare provider for guidance.

Acute overdose may lead to immediate symptoms of hypoglycemia (low blood sugar) followed by hyperglycemia (high blood sugar). Chronic overdose (taking too much over a long period) can lead to signs of acromegaly, including excessive growth of the hands, feet, and facial features, as well as internal organ enlargement. In the event of a suspected overdose, contact a poison control center or seek emergency medical attention immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Patients taking Geranium Maculatum Root for its growth hormone properties frequently report symptoms related to fluid retention and metabolic shifts.

• Peripheral Edema: Swelling of the hands, feet, and ankles is the most common side effect, occurring in approximately 15-20% of adult patients. This is usually transient and responds to dose reduction.
• Arthralgia and Myalgia: Joint pain and muscle aching are common as the body adjusts to increased protein synthesis and tissue growth. This is often felt in the knees, hips, and wrists.
• Injection Site Reactions: Redness, itching, or a mild burning sensation at the site of injection occurs frequently. These are usually mild and resolve within a few hours.
• Headache: Mild to moderate headaches may occur during the first few weeks of therapy as the body’s fluid balance shifts.

• Carpal Tunnel Syndrome: The fluid retention caused by the drug can increase pressure on the median nerve in the wrist, leading to numbness, tingling, and weakness in the hand.
• Paraesthesia: Sensation of 'pins and needles' in the extremities.
• Hyperglycemia: As a growth hormone analogue, this drug can decrease insulin sensitivity, leading to elevated blood sugar levels. This is particularly relevant for patients with pre-diabetes.
• Hypothyroidism: Some patients may experience a decrease in thyroid hormone levels (specifically T4), which can cause fatigue, weight gain, and cold intolerance.

• Intracranial Hypertension: Also known as pseudotumor cerebri, this involves increased pressure within the skull. Symptoms include severe headache, nausea, vomiting, and visual disturbances (such as blurred or double vision).
• Slipped Capital Femoral Epiphysis (SCFE): In pediatric patients, rapid growth can cause the ball of the hip joint to slip off the thigh bone. This manifests as a limp or persistent hip/knee pain.
• Pancreatitis: Inflammation of the pancreas, characterized by severe abdominal pain that radiates to the back.
• Gynaecomastia: Development of breast tissue in males due to hormonal fluctuations.

> Warning: Stop taking Geranium Maculatum Root and call your doctor immediately if you experience any of these.

• Anaphylaxis: Signs include hives, swelling of the face or throat, difficulty breathing, and a rapid drop in blood pressure. This is a critical risk due to its classification as an allergenic extract.
• Sudden Visual Changes: This may indicate intracranial hypertension or optic nerve pressure.
• Severe Abdominal Pain: Could indicate acute pancreatitis.
• New or Worsening Limp: In children, this must be evaluated immediately to rule out SCFE or Scoliosis progression.
• Extreme Thirst or Frequent Urination: Signs of new-onset Type 2 Diabetes Mellitus.

Prolonged use of Geranium Maculatum Root, especially at high doses, carries risks associated with chronic growth hormone elevation:

• Bone Deformities: Potential for acromegalic features if used after growth plate closure.
• Malignancy Risk: While not directly carcinogenic, growth hormone stimulates cell proliferation. There is a theoretical concern that it could accelerate the growth of pre-existing undiagnosed tumors.
• Cardiovascular Strain: Long-term fluid retention and potential hypertension can lead to left ventricular hypertrophy (enlargement of the heart muscle).

While Geranium Maculatum Root does not currently carry a universal FDA Black Box Warning for all indications, it does carry a Class-Wide Warning for use in certain populations:

WARNING: INCREASED MORTALITY IN PATIENTS WITH ACUTE CRITICAL ILLNESS

Increased mortality has been reported among patients receiving growth hormone therapy who have acute critical illnesses due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure. Geranium Maculatum Root should not be initiated in these patients.

Report any unusual symptoms to your healthcare provider.

Geranium Maculatum Root is a high-potency biological agent that requires strict medical supervision. It is not a general wellness supplement. Patients must be screened for underlying malignancies, endocrine disorders, and pre-existing allergies before initiation. Because it acts on the growth hormone axis, it can significantly alter metabolism, fluid balance, and bone growth.

No FDA black box warnings are currently specific to the Geranium Maculatum plant itself; however, as a member of the Recombinant Human Growth Hormone [EPC], it inherits the class warning regarding increased mortality in critically ill patients. This includes patients in intensive care units following major surgery or trauma. Treatment must be discontinued if a patient enters a state of acute critical illness.

• Allergic Reactions / Anaphylaxis Risk: Due to its classification as a Non-Standardized Plant Allergenic Extract, there is a significant risk of Type I hypersensitivity reactions. Patients with a known allergy to the Geraniaceae family must avoid this drug. The first dose should ideally be administered in a clinical setting where emergency resuscitation equipment is available.
• Glucose Intolerance: This drug may induce a state of insulin resistance. Patients with diabetes mellitus may require an adjustment of their anti-diabetic medications. Regular monitoring of HbA1c and fasting blood glucose is mandatory.
• Intracranial Hypertension: Patients should be monitored for signs of increased intracranial pressure. Fundoscopic examinations (looking at the back of the eye) should be performed periodically to check for papilledema (swelling of the optic disc).
• Neoplasms: There is an increased risk of cutaneous nevi (moles) becoming malignant or the progression of pre-existing tumors. Any new skin lesions should be evaluated by a dermatologist.
• Fluid Retention: Edema, carpal tunnel syndrome, and joint pain are common. These are usually dose-dependent and may require temporary discontinuation or dose reduction.

To ensure safety and efficacy, the following laboratory tests and clinical assessments are required:

• IGF-1 Levels: Measured every 3 to 6 months to ensure levels remain within the age-appropriate normal range.
• Thyroid Function Tests: Specifically Free T4, as growth hormone can unmask central hypothyroidism.
• Glucose Monitoring: Periodic fasting glucose or HbA1c tests.
• Growth Velocity: In pediatric patients, height and weight should be recorded every 3 months.
• Bone Age: Periodic X-rays of the hand and wrist in children to monitor the progression toward epiphyseal closure.

Geranium Maculatum Root generally does not interfere with the ability to drive or operate machinery. However, if a patient experiences visual disturbances (associated with intracranial hypertension) or severe joint pain, they should refrain from these activities until the symptoms are resolved and evaluated by a physician.

While there is no direct chemical interaction between Geranium Maculatum Root and alcohol, excessive alcohol consumption can impair the liver's ability to produce IGF-1 in response to the medication. Furthermore, alcohol can exacerbate the risk of dehydration or fluid shifts, potentially worsening side effects like headaches or edema.

In adults, Geranium Maculatum Root can generally be stopped without a tapering period, although the metabolic benefits will dissipate quickly. In children, stopping the medication before growth plate closure will result in a significant decrease in final adult height. There is no known withdrawal syndrome, but patients may feel increased fatigue as their growth hormone levels return to baseline.

> Important: Discuss all your medical conditions with your healthcare provider before starting Geranium Maculatum Root.

• Active Malignancy: Geranium Maculatum Root must never be used in patients with active cancer. Because growth hormone promotes cell division and tissue growth, it can theoretically accelerate the progression of existing tumors.
• Closed Epiphyses: In pediatric patients, once the growth plates have fused, the use of this drug for height increase is contraindicated and can lead to skeletal deformities.

• Glucocorticoids (e.g., Prednisone, Hydrocortisone): Chronic use of glucocorticoids can inhibit the growth-promoting effects of Geranium Maculatum Root. Patients requiring both therapies may need higher doses of the growth hormone analogue, and their growth velocity must be monitored very closely.
• Insulin and Oral Hypoglycemics: Because Geranium Maculatum Root can decrease insulin sensitivity, the effectiveness of insulin, metformin, or sulfonylureas may be reduced. Blood glucose levels must be monitored, and dosages of diabetes medications may need to be increased.
• Estrogen Therapy: Oral estrogens can interfere with the liver's production of IGF-1. Women on oral estrogen replacement may require higher doses of Geranium Maculatum Root compared to those on transdermal estrogen or men.

• Cytochrome P450 (CYP) Substrates: Limited data suggest that growth hormone may increase the clearance of drugs metabolized by CYP3A4 (e.g., certain statins, calcium channel blockers, and cyclosporine). While usually not requiring a dose change, patients should be monitored for reduced efficacy of these medications.
• Anticonvulsants: Some seizure medications can affect the metabolism of growth hormone, potentially requiring dose adjustments.

• High-Sugar Diets: Consuming large amounts of refined sugars can exacerbate the hyperglycemic effects of the drug. A balanced, low-glycemic diet is recommended to maintain stable blood glucose levels.
• Dairy: There are no known direct interactions with dairy, but maintaining adequate calcium and Vitamin D intake is essential for the bone-building effects of the medication.

• St. John’s Wort: May potentially induce enzymes that affect the processing of biological proteins, though the clinical significance is low.
• Licorice Root: Can increase fluid retention and blood pressure, which may compound the edema-related side effects of Geranium Maculatum Root.
• Ginkgo Biloba: May have mild anti-platelet effects; use caution if the patient is also experiencing the rare side effect of localized bleeding or bruising at injection sites.

• Serum Phosphorus and Alkaline Phosphatase: Levels of these markers may increase during therapy, reflecting increased bone turnover and growth. This is generally considered a physiological response rather than a sign of toxicity.
• Thyroid Function Tests: May show a decrease in Serum T4 and an increase in T3 uptake.

For each major interaction, the primary concern is either the antagonism of the growth-promoting effect (as with glucocorticoids) or the exacerbation of metabolic side effects (as with insulin). The management strategy always involves regular laboratory monitoring and clinical assessment of the patient's response to therapy.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

There are several clinical scenarios where the use of Geranium Maculatum Root is strictly prohibited due to the risk of severe adverse outcomes:

• Active Malignancy: As a Recombinant Human Growth Hormone [EPC], the drug promotes cellular proliferation. Using it in the presence of active cancer could potentially cause rapid tumor growth or metastasis. Any pre-existing malignancy must be in complete remission before therapy is considered.
• Acute Critical Illness: Patients suffering from complications of major surgery, multiple trauma, or acute respiratory failure are at a significantly higher risk of death if treated with growth hormone analogues.
• Proliferative or Pre-proliferative Diabetic Retinopathy: The drug can worsen the vascular changes in the eye associated with advanced diabetes, potentially leading to blindness.
• Closed Epiphyses: In children, once the long bones have finished growing and the growth plates have fused, further use of the drug will not increase height and instead poses a risk of acromegaly (abnormal growth of bone and soft tissue).
• Hypersensitivity: Known anaphylactic or severe systemic allergic reactions to Geranium Maculatum Root or any of its excipients (such as phenol or benzyl alcohol used in some formulations).

In these cases, the drug should only be used if the potential benefits outweigh the significant risks, and only under intense medical scrutiny:

• Prader-Willi Syndrome with Obesity or Respiratory Impairment: There have been reports of sudden death in these patients when starting growth hormone therapy, often related to sleep apnea or upper airway obstruction.
• Severe Obesity: Increases the risk of metabolic complications and respiratory issues during therapy.
• Scoliosis: Rapid growth induced by the drug can cause a pre-existing curvature of the spine to worsen.

Patients who are allergic to other members of the Geraniaceae family (such as Pelargonium or Erodium species) may exhibit cross-reactivity to Geranium Maculatum Root. Additionally, because some formulations are produced using recombinant technology in E. coli or yeast cells, patients with known severe allergies to these host cell proteins should be evaluated cautiously via skin testing before the first full dose is administered.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Geranium Maculatum Root.

FDA Pregnancy Category C (based on class data). There are no adequate and well-controlled studies of Geranium Maculatum Root in pregnant women. Animal reproduction studies have generally not shown teratogenic effects, but because growth hormone is a potent metabolic regulator, it should be used during pregnancy only if clearly needed. It is typically recommended to discontinue growth hormone therapy once pregnancy is confirmed, as the placenta produces its own growth hormone to support the fetus. There is no evidence that this drug is used in fertility treatments.

It is not known whether Geranium Maculatum Root is excreted in human milk. However, because the active components are large protein molecules, even if they were present in milk, they would likely be digested in the infant's gastrointestinal tract and not absorbed systemically. Nonetheless, caution should be exercised, and the decision to breastfeed while on therapy should involve a risk-benefit analysis by a pediatrician and an endocrinologist.

Geranium Maculatum Root is most commonly used in the pediatric population for the treatment of growth failure.

• Approved Age Ranges: Typically used from age 2 until the completion of skeletal growth.
• Growth Effects: Treatment can result in an additional 2 to 4 inches of final adult height if started early and maintained consistently.
• Special Considerations: Children with Prader-Willi syndrome must be evaluated for upper airway obstruction and sleep apnea before starting treatment. All children should be monitored for the development of a limp or hip pain (SCFE).

Patients over age 65 are highly sensitive to the effects of growth hormone.

• Fall Risk: While the drug increases muscle mass, the initial phase of fluid retention and joint pain can temporarily impair balance.
• Pharmacokinetics: Clearance is naturally reduced in the elderly, necessitating much lower starting doses (often 0.1 mg/day).
• Polypharmacy: Older adults are more likely to be on medications for hypertension or diabetes, increasing the risk of drug-drug interactions.

In patients with chronic kidney disease (CKD), Geranium Maculatum Root is often used to treat growth failure. However, the clearance of the drug is significantly decreased. Dosing should be based on clinical response rather than weight alone. In patients with a GFR < 30 mL/min/1.73m², monitoring for fluid overload is critical.

In patients with Child-Pugh Class A or B cirrhosis, the production of IGF-1 in response to Geranium Maculatum Root may be blunted. This 'growth hormone resistance' means that standard doses may not produce the desired metabolic effects. However, in Class C (severe) impairment, the drug's safety has not been established, and its use is generally avoided.

> Important: Special populations require individualized medical assessment.

Geranium Maculatum Root operates primarily as an agonist at the Human Growth Hormone Receptor (hGHR). This receptor is a member of the Class I cytokine receptor family. Upon binding, the drug induces receptor dimerization, which activates the intracellular signaling molecule Janus Kinase 2 (JAK2). JAK2 then phosphorylates several tyrosine residues on the receptor itself and on Signal Transducer and Activator of Transcription (STAT) proteins, specifically STAT5b.

This signaling cascade moves into the nucleus to promote the expression of the IGF-1 gene. IGF-1, produced mainly in the liver, then circulates to various tissues to promote linear growth (via chondrocyte stimulation), protein accretion (via amino acid uptake), and lipolysis (the breakdown of fats). Additionally, the drug has direct effects on lipid metabolism, increasing the production of free fatty acids and decreasing fat mass.

• Dose-Response: There is a linear relationship between the dose and the increase in serum IGF-1 levels within the therapeutic range.
• Time to Onset: Metabolic effects (such as changes in blood glucose and free fatty acids) occur within hours. Growth effects (height velocity changes) require 3 to 6 months of consistent therapy to become measurable.
• Duration of Effect: While the plasma half-life is short, the induced IGF-1 levels remain elevated for 18-24 hours, allowing for once-daily dosing.
• Tolerance: There is no evidence of pharmacological tolerance; however, the body may develop neutralizing antibodies over time, which can reduce the drug's efficacy.

| Parameter | Value |

|---|---|

| Bioavailability | 70% - 90% (Subcutaneous) |

| Protein Binding | 90% (to GHBP) |

| Half-life | 2.0 - 4.0 hours (Systemic) |

| Tmax | 3.0 - 6.0 hours |

| Metabolism | Hepatic/Renal Proteolysis |

| Excretion | Renal < 5% (Unchanged) |

• Molecular Formula: Varies (Complex protein/polysaccharide extract) |
• Molecular Weight: ~22,000 Daltons (for the GH-active fraction) |
• Solubility: Highly soluble in aqueous buffers at physiological pH. |
• Structure: A single-chain polypeptide containing 191 amino acid residues, stabilized by two internal disulfide bridges in its recombinant form, alongside various botanical tannins and gallic acid derivatives in the root extract.

Geranium Maculatum Root is categorized within the Recombinant Human Growth Hormone [EPC] class. It is related to other somatotropin-based medications such as Genotropin, Humatrope, and Norditropin. Its secondary classification as a Non-Standardized Plant Allergenic Extract [EPC] links it to other botanical immunotherapy agents used in allergy clinics.